Guardant Health IncGH
Price$174.75

Outlook & Key Dates

Estimates, guidance, catalysts, and upcoming events

Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
71.6%projected annual EPS growth
As of 27 Aug 2026
Analyst Coverage
24analysts covering
Consensus: PositiveAs of 18 Aug 2026
FY Revenue (est.)
$1.4Bnext fiscal year
As of 18 Aug 2026
FY EPS (est.)
-$1.45next fiscal year
As of 18 Aug 2026
Monitoring Framework
Key Performance Indicators
Oncology Test Volume Quarterly86K
Screening Test Volume (Shield) Quarterly44K
Total Revenue Quarterly301.7MTarget: $1.30 to $1.32 billion
Watch Items
  • Medicare Reimbursement Rate for Shield CRC Test
  • Executive Compensation Say-on-Pay Advisory Vote
Sign in / Sign up to read more

Research as of 2 Sep 2026

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.